The Future of Biosimilars in the USA Can pharma resolve the litigation frenzy hampering biosimilars' market entry in the US? Is too much focus on legal wrangling stifling healthy competition and innovation? And, as the...

Education is top priority as biosimilar mAbs enter the market With the recent approval of Celltrion’s Truxima, all eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next...

Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out…  Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers...

What is the future for biosimilars in the EU? What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars? In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of...

How to educate stakeholders about biosimilar benefits What information and data do physicians, payers and patients need about biosimilars? As the market expands and new therapeutic sectors come on stream, more...

Development activity is surging as the focus shifts to commercialisation. How will the market evolve? The race to commercialise biosimilars is on. What will it take to create a thriving market? Will payers see real cost...

What’s driving the uptake of biosimilars in Europe and what still needs to be done? The European market for biosimilars has seen a year of progress and change, with more therapies available and changing...

Biosimilars offer a chance to improve access to, and reduce spending on, life-saving biologic therapies. But could regulators do more to support the market? While experts believe significant regulatory progress has been...